Effect of sibutramine on blood pressure in patients with obesity and well-controlled hypertension or normotension

Endocrine Practice

Volumn 11, Issue 5, 2005, Pages 308-312

  Gürsoy, Alptekin ^a   Erdoǧan, Murat Faik ^a   Cin, Mine Özduman ^a   Cesur, Mustafa ^a   Başkal, Nilgün ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANOREXIGENIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOBUTANE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SIBUTRAMINE;

ADULT; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; FEMALE; HEART RATE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; APPETITE DEPRESSANTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; CYCLOBUTANES; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OBESITY; TIME FACTORS;

EID: 33644987761     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.11.5.308     Document Type: Article

References (23)

1. National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. NIH publication 98-4083. September 1998. Available at: http://www.nhlbi.nih.gov/guidelines/obesity/ob-gdlns.pdf. Accessed for verification June 8, 2005.
2. Collazo-Clavell ML. Safe and effective management of the obese patient. Mayo Clin Proc. 1999;74:1255-1259.
3. Ryan DH. Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity. Endocrine. 2000;13:193-199.
4. Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT (Sustained-Release Dexfenfluramine Study Group). An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. N Engl J Med. 1998;339:725-732.
5. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med. 1998;339:719-724.
6. Khan MA, Herzog CA, St Peter JV, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med. 1998;339: 713-718.
7. Dickerson LM, Carek PJ. Drug therapy for obesity. Am Fam Physician. 2000;61:2131-2138, 2143.
8. McNeely W, Goa KL. Sibutramine: a review of its contribution to the management of obesity. Drugs. 1998;56: 1093-1124.
9. Luque CA, Rey JA. The discovery and status of sibutramine as an anti-obesity drug. Eur J Pharmacol. 2002; 440:119-128.
10. Nisoli E, Carruba MO. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev. 2000;1:127-139.
11. McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K (Sibutramine in Hypertensives Clinical Study Group). Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens. 2002;16:5-11.
12. McMahon FG, Fujioka K, Singh BN, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med. 2000;160:2185-2191.
13. Fujioka K, Seaton TB, Rowe E, et al (Sibutramine/Diabetes Clinical Study Group). Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2000;2:175-187.
14. Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss. Obes Res. 1999;7:189-198.
15. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord. 1999;23:1016-1024.
16. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E.. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med. 1999;106:179-184.
17. Ersoz HO, Ukinc K, Baykan M, et al. Effect of low-dose metoprolol in combination with sibutramine therapy in normotensive obese patients: a randomized controlled study. Int J Obes Relat Metab Disord. 2004;28:378-383.
18. Faria AN, Ribeiro Filho FF, Lerario DD, Kohlmann N, Ferreira SR, Zanella MT. Effects of sibutramine on the treatment of obesity in patients with arterial hypertension [article in English, Portuguese]. Arq Bras Cardiol. 2002; 78:172-180.
19. Hazenberg BP. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology. 2000;94:152-158.
20. Zannad F, Gille B, Grentzinger A, et al. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J. 2002; 144:508-515.
21. McGrath BP (National Blood Pressure Advisory Committee of the National Heart Foundation of Australia). Ambulatory blood pressure monitoring. Med J Aust. 2002;176:588-592.
22. Kim SH, Lee YM, Jee SH, Nam CM. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res. 2003;11:1116-1123.
23. Sharma AM, Pirner MA, Hewkin A, et al. Effect of sibutramine versus placebo on blood pressure in randomized, double-blind controlled trials: a retrospective analysis [abstract]. Obes Res. 2003;11(Suppl):A110.